MedTrace Logo

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

NCT03573882 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2025-11-18

Study results available
· View outcomes & findings →

Summary

Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials

Conditions

Interventions

DRUG

Voxelotor

300mg or 500mg Tablet, Oral, With or Without Food

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-06
Primary Completion
2024-11-12
Completion
2024-11-12
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Egypt
  • France
  • Italy
  • Kenya
  • Lebanon
  • Netherlands
  • Oman
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03573882 on ClinicalTrials.gov